Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

Changes in serum cartilage oligomeric matrix protein (COMP) were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept, to elucidate whether the favourable results of tissue protection reported in clinical trials are corrob...

Full beskrivning

Bibliografiska uppgifter

I publikationen:	Arthritis Res Ther
Huvudupphov:	Crnkic, Meliha, Månsson, Bengt, Larsson, Lotta, Geborek, Pierre, Heinegård, Dick, Saxne, Tore
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2003
Ämnen:	Research Article
Länkar:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165057/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823852/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar760
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!